ECCO 2017 | Prostate cancer: novel tracers in choline PET/CT

Stefano Fanti, MD of University of Bologna, Bologna, Italy discusses the use of nuclear medicine in prostate cancer at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. In nuclear medicine, radiopharmaceuticals are targeted to a ligand, a receptor, or a molecular pathway, and detected, for example, using PET/CT. Choline PET/CT is typically used in prostate cancer, however it does have a lower sensitivity than FDG. Novel tracers are being developed, for example PSMA, which is labelled with gallium, fluorinator PSMA, and bombazine.